Nadia Gisella Di Muzio

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Paolo Passoni · 10 shared papers, 2012–2026 · strength 1.05
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancrea… DOI 10.3390/cancers17061036↗
   • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
2. Michele Reni · 8 shared papers, 2012–2026 · strength 0.95
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancrea… DOI 10.3390/cancers17061036↗
   • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
3. Claudio Fiorino · 6 shared papers, 2018–2026 · strength 0.93
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancrea… DOI 10.3390/cancers17061036↗
   • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
4. Maria Picchio · 5 shared papers, 2012–2026 · strength 0.63
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancrea… DOI 10.3390/cancers17061036↗
   • Paper Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemo… DOI 10.1016/j.radonc.2020.07.003↗
5. Martina Mori · 4 shared papers, 2018–2025 · strength 0.52
   • Paper Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancrea… DOI 10.3390/cancers17061036↗
   • Paper Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in… DOI 10.3389/fonc.2022.983984↗
   • Paper Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemo… DOI 10.1016/j.radonc.2020.07.003↗
6. Sara Broggi · 4 shared papers, 2018–2024 · strength 0.49
   • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
   • Paper Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in… DOI 10.3389/fonc.2022.983984↗
   • Paper Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemo… DOI 10.1016/j.radonc.2020.07.003↗
7. M. De Vincenzi · 2 shared papers, 2025–2026 · strength 0.43
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancrea… DOI 10.3390/cancers17061036↗
8. Marina Macchini · 2 shared papers, 2024–2026 · strength 0.40
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
9. Giulia Orsi · 2 shared papers, 2024–2026 · strength 0.40
   • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
   • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
10. Giovanni Mauro Cattaneo · 4 shared papers, 2013–2022 · strength 0.28
    • Paper Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in… DOI 10.3389/fonc.2022.983984↗
    • Paper Quantifying the robustness of [18F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and … DOI 10.1016/j.ejmp.2018.05.013↗
    • Paper Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotation… DOI 10.1016/j.radonc.2013.05.011↗
11. Gianpaolo Balzano · 3 shared papers, 2012–2024 · strength 0.24
    • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
    • Paper Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vess… DOI 10.1016/j.ijrobp.2013.09.012↗
    • Paper Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancrea… DOI 10.1245/s10434-011-2205-2↗
12. Martina Mori · 1 shared paper, 2026 · strength 0.22
    • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
13. Catia Carconi · 1 shared paper, 2026 · strength 0.22
    • Paper A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemot… DOI 10.1016/j.dld.2026.09.026↗
14. Umberto Peretti · 1 shared paper, 2024 · strength 0.18
    • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
15. Giulio Belfiori · 1 shared paper, 2024 · strength 0.18
    • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
16. Domenico Tamburrino · 1 shared paper, 2024 · strength 0.18
    • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
17. Massimo Falconi · 1 shared paper, 2024 · strength 0.18
    • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
18. Stefano Cascinu · 1 shared paper, 2024 · strength 0.18
    • Paper Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocar… DOI 10.1016/j.ctro.2024.100778↗
19. R. Calandrino · 3 shared papers, 2013–2018 · strength 0.14
    • Paper Quantifying the robustness of [18F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and … DOI 10.1016/j.ejmp.2018.05.013↗
    • Paper Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotation… DOI 10.1016/j.radonc.2013.05.011↗
    • Paper Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vess… DOI 10.1016/j.ijrobp.2013.09.012↗
20. Stefano Cereda · 3 shared papers, 2012–2013 · strength 0.09
    • Paper Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotation… DOI 10.1016/j.radonc.2013.05.011↗
    • Paper Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vess… DOI 10.1016/j.ijrobp.2013.09.012↗
    • Paper Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancrea… DOI 10.1245/s10434-011-2205-2↗
21. Maria Luisa Belli · 1 shared paper, 2018 · strength 0.07
    • Paper Quantifying the robustness of [18F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and … DOI 10.1016/j.ejmp.2018.05.013↗
22. Cristina Messa · 1 shared paper, 2012 · strength 0.03
    • Paper Role of PET/CT in the clinical management of locally advanced pancreatic cancer. DOI 10.1177/030089161209800516↗
23. Piercarlo Saletti · 1 shared paper, 2012 · strength 0.03
    • Paper Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancrea… DOI 10.1245/s10434-011-2205-2↗
24. Carlo Milandri · 1 shared paper, 2012 · strength 0.03
    • Paper Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancrea… DOI 10.1245/s10434-011-2205-2↗
25. Eugenio Villa · 1 shared paper, 2012 · strength 0.03
    • Paper Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancrea… DOI 10.1245/s10434-011-2205-2↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.